Bayer, Balances

Bayer Balances Biologics Push and $672 Million Loss Against Raised Guidance

Published on 11/17/2026 at 21:31 | Editorial boerse-global.de
Bayer plans 17 new biological crop protection products for Latin America by 2030, as Q3 2026 brought a €672 million loss but raised full-year guidance.
Bayer, Balances, Biologics, Push, Loss, Against, Raised, Guidance, Latin, America Illustration mit AI erstellt.

Bayer is plotting a significant expansion of its biological crop protection portfolio in Latin America, even as the German group works through a mixed third-quarter 2026 that paired a net loss with improved full-year targets.

The company intends to bring 17 new biological plant protection and plant performance products to Latin America by 2030, with eight of those slated for launch in Brazil, according to a Reuters report dated November 4. The move is designed to deepen Bayer's presence in a fast-growing regional market for biological agricultural inputs.

A Quarter of Contrasts

On November 3, Bayer reported a group loss of 672 million euros for the third quarter of 2026, while still delivering positive EBITDA before special items. Revenue for the reporting period came in at 10.1 billion euros, with adjusted EBITDA reaching 1.62 billion euros.

Alongside the quarterly figures, the group lifted its guidance for the Pharmaceuticals margin and free cash flow, and said it expects lower net financial debt. For full-year adjusted group EBITDA, Bayer raised its outlook to a range of 9.8 to 10.3 billion euros, up from a prior forecast of 9.6 to 10.1 billion euros.

Should investors sell immediately? Or is it worth buying Bayer?

DZ Bank Sees Stabilization

The DZ Bank weighed in on November 5, lifting its fair value for Bayer to 64 euros from 60 euros and keeping its "Buy" rating. Analyst Peter Spengler pointed to operational stabilization, debt reduction and progress on US legal risks as the pillars behind the upgrade.

Two Approvals in Quick Succession

Bayer's pharmaceutical pipeline delivered a pair of regulatory wins in short order. Late last week, the FDA cleared Asundexian under the brand name Sunharbo to reduce the risk of recurrent strokes in certain adults, administered in combination with an antiplatelet agent. Bayer described the compound as the first approved drug worldwide in its class, an inhibitor of factor XIa. Shipments are set to begin in the US between mid and late November.

Earlier in November, China approved Sevabertinib as a first-line treatment for patients with HER2-mutated advanced non-small cell lung cancer.

Bayer at a turning point? This analysis reveals what investors need to know now.

Analysts Split on the Outlook

Deutsche Bank Research raised its price target to 65 euros from 60 euros last Tuesday, reaffirming its Buy call. Analyst Virginie Boucher-Ferte lifted her EBITDA and earnings-per-share estimates for 2027 and 2028 following the quarterly results.

Jefferies, by contrast, kept its Hold rating and a 48.50-euro target the same day. Analyst Michael Leuchten highlighted the significance of the Asundexian approval for the risk profile of the pharma pipeline.

Ad

Bayer Stock: New Analysis - 17 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70528623 |